Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

novel antiplatelet agent that can potentially prevent the formation of deadly blood clots without adding a significant bleeding risk (in Phase III); approximately 13,000 patients have been enrolled in its Phase III program targeted to include 30,000 patients;
  • SIMPONI(TM)* (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets;
  • SAPHRIS(TM)** (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder); pivotal relapse-prevention data were presented showing that only 12 percent of patients receiving asenapine relapsed at the specified endpoint versus 47 percent of patients receiving placebo;
  • BRIDION(R) (sugammadex), the first and only selective relaxant binding agent for reversing neuromuscular blockade in anesthesia (approved in EU; under review in U.S. and Japan);
  • Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ribavirin combination therapy (in Phase III); 24-week sustained viral response (SVR) data were presented showing that 75 percent of patients achieved SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was unveiled, with the potential to offer once-daily dosing and having 10 times the in vitro potency of current protease inhibitors in late-phase development;
  • Mometasone furoate and formoterol (MFF), an inhaled combination therapy for asthma and COPD (completing Phase III); pivotal data from Phase III trials in asthma were presented showing that MFF met its primary endpoints; and
  • Preladenant, a nov
    '/>"/>

  • SOURCE Schering-Plough Corporation
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
    2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
    3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
    4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
    5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
    6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
    7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
    8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
    11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
    (Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
    (Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
    Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
    ... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
    ... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
    Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
    (Date:8/29/2014)... August 29, 2014 RBS Reputation Management has ... Book. The service is to help those individuals and ... them on Scam Book. The service would push down the ... Scam Book complaints fully invisible on Google. , RBS ... , On being asked how company can provide guarantee of ...
    (Date:8/29/2014)... August 29, 2014 A home should be a ... if unaddressed. That’s why Amica Insurance is sharing some tips to ... Council suggests taking the following safety measures: , Kitchen, ... in their original containers, and keep them away from food. ... bracket near an exit. , Bathroom , ...
    (Date:8/29/2014)... has caused disease outbreaks across the Arabian Peninsula and ... has claimed the lives of several hundred people since ... have been puzzled over how easily the pathogen spreads ... led by virologists from the University of Bonn have ... the rate of human transmission is low. Still, a ...
    (Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
    (Date:8/29/2014)... 29, 2014 VHA Central Atlantic recognized ... in clinical care, honoring nine facilities for meeting or ... , “At Novant Health, providing quality, affordable healthcare for ... Tom Zweng, MD, executive vice president and chief medical ... a remarkable experience for each and every one of ...
    Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
    ... Million Required for Immediate Needs, NEW YORK, May ... China in a generation, news of its full impact ... trickling in at a,painfully slow speed., According to ... personnel by parachute from the air. The agency also ...
    ... obesity is a key culprit, study says , , WEDNESDAY, May ... in childhood, and that means preventive measures must be embraced ... Two of the biggest threats to heart health that trace ... official high blood pressure reading of 140/90 -- and obesity. ...
    ... May 14 AlphaMed Press, publisher of ... Oncologist, has,promoted George Kendall Vice President, Operations ... ), Ann Murphy, AlphaMed,s president, ... journals, Stem Cells and The Oncologist, and ...
    ... Charles (Charlie),Goldstein was honored with the first California ... at his home in Los Angeles,surrounded by family, ... passed away the following night. He was 87 ... The CDA Foundation Humanitarian Award was recently established ...
    ... Care, WASHINGTON, May 14 The nation,s leading,organization ... on Aging to look to assisted living providers for ... Richard Grimes, the CEO and President of the Assisted ... as it launched,hearings on the impact on Americans of ...
    ... Association (AVMA) declared a preliminary victory on several ... and pledging to,continue working toward the implementation of ... joint U.S. House of Representatives and,Senate conference committee, ... health that ranges from food safety protection and ...
    Cached Medicine News:Health News:UNICEF Rushing Medical Supplies, Tents, Clean Water to Children Affected by Powerful Earthquake in China 2Health News:Heart Disease Starts Early in Life 2Health News:Heart Disease Starts Early in Life 3Health News:AlphaMed Press Names George Kendall Vice President, Operations and Business Development 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 3Health News:Assisted Living Industry Looks at Future of Alzheimer's 2Health News:AVMA Declares Preliminary Victory on Farm Bill Provisions 2
    ... bleeding time devices provides the choice of ... for children and Surgicutt Newborn for newborns. ... to perfect the bleeding time test and ... have previously hindered test standardization. The device ...
    ... The revolutionary new design of the ... use. Every feature has been designed with ... for easy removal to the ergonomic thumb-groove ... linear tracked lance makes minimizing pain possible. ...
    The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
    Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
    Medicine Products: